BBIO — BridgeBio Pharma Balance Sheet
0.000.00%
Last trade - 00:00
- $4.54bn
- $5.85bn
- $9.30m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 546 | 607 | 837 | 472 | 435 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 569 | 643 | 889 | 549 | 478 |
Net Property, Plant And Equipment | 5.63 | 36.8 | 46 | 25.2 | 19.8 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 632 | 704 | 1,013 | 623 | 546 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 60.4 | 95.6 | 135 | 121 | 144 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 223 | 646 | 1,883 | 1,878 | 1,901 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 408 | 57.9 | -870 | -1,255 | -1,354 |
Total Liabilities & Shareholders' Equity | 632 | 704 | 1,013 | 623 | 546 |
Total Common Shares Outstanding |